Great Novel Therapeutics Biotech & Medicals Corp. Statistics
Great Novel Therapeutics Biotech & Medicals Corp. (7427) Stock Statistics & Valuation Metrics
Total Valuation
Great Novel Therapeutics Biotech & Medicals Corp. has a market cap or net worth of TWD 3.14B. The enterprise value is ―.
- Market Cap
- TWD 3.14B
- Enterprise Value
- ―
Share Statistics
Great Novel Therapeutics Biotech & Medicals Corp. has 54,026,234 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 54,026,234
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Great Novel Therapeutics Biotech & Medicals Corp.’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -19.49%.
- Return on Equity (ROE)
- -0.19
- Return on Assets (ROA)
- -0.19
- Return on Invested Capital (ROIC)
- -19.49%
- Return on Capital Employed (ROCE)
- -0.20
- Revenue Per Employee
- 52.39K
- Profits Per Employee
- -4.24M
- Employee Count
- 23
- Asset Turnover
- 0.00
- Inventory Turnover
- 1.38
Valuation Ratios
The current PE Ratio of Great Novel Therapeutics Biotech & Medicals Corp. is -24.47. Great Novel Therapeutics Biotech & Medicals Corp.’s PEG ratio is 1.25.
- PE Ratio
- -24.47
- PS Ratio
- 513.13
- PB Ratio
- 3.66
- Price to FCF
- -83.45
- Price to Operating Cash Flow
- -31.36
- PEG Ratio
- 1.25
Income Statement
In the last 12 months, Great Novel Therapeutics Biotech & Medicals Corp. had revenue of 1.21M and earned -97.47M in profits. Earnings per share was -2.15.
- Revenue
- 1.21M
- Gross Profit
- -8.87M
- Operating Income
- -99.54M
- Pretax Income
- -97.47M
- Net Income
- -97.47M
- EBITDA
- -91.86M
- Earnings Per Share (EPS)
- -2.15
Cash Flow
In the last 12 months, operating cash flow was -87.92M and capital expenditures 49.75M, giving a free cash flow of -38.17M billion.
- Operating Cash Flow
- -87.92M
- Free Cash Flow
- -38.17M
- Free Cash Flow per Share
- -0.83
Dividends & Yields
Great Novel Therapeutics Biotech & Medicals Corp. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.21%
- Earnings Yield
- -4.10%
Stock Price Statistics
- Beta
- 0.21
- 52-Week Price Change
- 72.33%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 29.80
- Average Volume (3m)
- 325.64K
Financial Position
Great Novel Therapeutics Biotech & Medicals Corp. as a current ratio of 24.12, with Debt / Equity ratio of 1.56%
- Current Ratio
- 24.12
- Quick Ratio
- 23.74
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.24
- Interest Coverage Ratio
- -1026.23
Taxes
In the past 12 months, Great Novel Therapeutics Biotech & Medicals Corp. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Great Novel Therapeutics Biotech & Medicals Corp. EV to EBITDA ratio is -27.92, with an EV/FCF ratio of -80.65.
- EV to Sales
- 495.91
- EV to EBITDA
- -27.92
- EV to Free Cash Flow
- -80.65
- EV to Operating Cash Flow
- -35.01
Balance Sheet
Great Novel Therapeutics Biotech & Medicals Corp. has TWD 698.97M in cash and marketable securities with TWD 6.43M in debt, giving a net cash position of TWD 692.53M billion.
- Cash & Marketable Securities
- TWD 698.97M
- Total Debt
- TWD 6.43M
- Net Cash
- TWD 692.53M
- Net Cash Per Share
- TWD 12.82
- Tangible Book Value Per Share
- TWD 15.89
Margins
Gross margin is -91.22%, with operating margin of -1886.11%, and net profit margin of -1798.73%.
- Gross Margin
- -91.22%
- Operating Margin
- -1886.11%
- Pretax Margin
- -1798.73%
- Net Profit Margin
- -1798.73%
- EBITDA Margin
- -1776.18%
- EBIT Margin
- -1886.11%
Analyst Forecast
The average price target for Great Novel Therapeutics Biotech & Medicals Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 248.57%
- EPS Growth Forecast
- -27.86%
